Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30%
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …

Simple Summary Immunotherapy-based combinations represent the front-line standard of
care for metastatic clear cell renal cell carcinoma (mccRCC) patients. These combinations …

There have been significant advances in the treatment of urology cancers, with a number of
practice‐changing treatments. There is now greater clarity on the role of the use of …

While surgical resection has remained the mainstay of treatment in early-stage renal cell
carcinoma (RCC), therapeutic options in the advanced setting have remarkably expanded …

Simple Summary Renal cancer is within the top 10 most common malignancies worldwide,
of which clear cell histology represents the most common subtype in this cancer. Within the …

In the last fifteen years a better understanding of the biological processes promoting tumour
growth and progression led to an impressive revolution in metastatic renal cell carcinoma …

Background Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic
renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone …

Cabozantinib is an oral tyrosine kinase inhibitor (TKI) with activity against several receptors
involved in the angiogenesis pathway, including vascular endothelial growth factor receptor …

Background: Cabozantinib monotherapy is approved for the treatment of several types of
solid tumors. Investigation into the use of cabozantinib combined with other therapies is …

PURPOSE Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have
greatly evolved. However, the availability of emerging options in global health care systems …